Indoxyl sulfate: clinical implications for anemia management in chronic kidney disease
The review synthesizes evidence from clinical and experimental studies that position indoxyl sulfate as a central yet underappreciated mediator of anemia in chronic kidney disease. Indoxyl sulfate establishes a vicious cycle that exacerbates anemia and contributes to erytropoiesis-stimulating agent hyporesponsiveness. The article advocates for targeted interventions aimed at reducing indoxyl sulfate burden, which could transform anemia management in chronic kidney disease and pave the way for personalized treatment strategies.
Authors
- Manoch Rattanasompattikul (ORCID: https://orcid.org/0000-0002-1150-2597)
- Kajohnsak Noppakun (ORCID: https://orcid.org/0000-0002-5783-8766)
- Ekamol Tantisattamo (ORCID: https://orcid.org/0000-0003-0883-6892)
- Thatsaphan Srithongkul (ORCID: https://orcid.org/0000-0002-5860-3395)
Institutions
- Siriraj Hospital (TH)
- GTx (United States) (US)
- Pacific Northwest University of Health Sciences (US)
- UCLA Medical Center (US)
- University of California, Irvine Medical Center (US)
- Biomedical Research Institute (US)
- VA Long Beach Healthcare System (US)
- Beaumont Hospital, Troy (US)
- Harbor–UCLA Medical Center (US)
- Chiang Mai University (TH)
Publication Details
- Journal
- Current Opinion in Nephrology & Hypertension
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1097/mnh.0000000000001145
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00